Healthcare

Nova Mentis (OTC: NMLSF) Sees Rapid Enrollment in Autism Study

Databank to focus on mRNA neuroinflammatory markers and serotonin neuro-transmitters VANCOUVER, BC, April 28, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics […]

Newsmakers

NuRAN (OTC: NRRWF) Selected by a Tier 1 Mobile Operator for RPF for Thousands of Mobile Sites in the Middle East and Africa

Potential for thousands of sites Over 15 countries Over 50 Million population coverage QUEBEC, QC / April 28, 2022 / NuRAN Wireless Inc. (“NuRAN” or the “Company”) (CSE:NUR)(OTC PINK:NRRWF)(FSE:1RN), a leading rural telecommunications company, is pleased to […]

Newsmakers

Nextech AR (OTC: NEXCF) to Present at ESCP International Event With Google, IBM, Netflix, Salesforce

TORONTO, April 26, 2022—Nextech AR Solutions Corp. (“Nextech” or the “Company”) (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), a Metaverse Company and leading provider of augmented reality (“AR”) experience technologies and services today announced that […]

No Picture
Newsmakers

Cyngn (NASDAQ: CYN) Launches DriveMod Kit, a Fully-Equipped Autonomous Vehicle Hardware Integration Module

MENLO PARK, Calif., April 21, 2022—Cyngn (or the “Company”) (NASDAQ: CYN), a developer of innovative autonomous driving software solutions for industrial and commercial enterprises, today announced the official launch of DriveMod Kit, a turnkey autonomous […]

Newsmakers

DeepMarkit (OTC: MKTDF) Announces Strategic Initiative to Explore the Minting of Renewable Energy Certificates

Renewable Energy Certificate market size was valued at US$12.7 billion in 2021, which is projected to reach US$100 billion by 2030 The Company’s MintCarbon.io platform has the capability of seamlessly facilitating the minting of RECs into NFTs as with […]

Healthcare

PharmaDrug (OTC: LMLLF) Advances Oncology Program with Filing of Provisional Patent Following Positive Findings for the Combination of PD-001 and Frontline Chemotherapy in Prostate Cancer Study

Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced tumor […]